Press releases - UCB
2024年10月31日 · UCB Announces Bepranemab Phase 2a Study Results Accepted for Late-Breaking Presentation at Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting. Read More.
UCB managed 2022 headwinds and is ready for 2023 launches
UCB expects to receive initial feedback for Europe in Q1/Q2 2024. In Q4 2022, UCB initiated a Phase 2a (proof-of-concept) study to evaluate the efficacy and safety of rozanolixizumab to treat adult study participants with severe fibromyalgia syndrome. First topline results are expected in …
Newsroom - UCB
UCB on YouTube. More videos. Resources. Access our media image selection or contact us for particular requests. View all resources. Contact. The UCB media relations team responds to calls and emails from professional journalists only. Contact us. Choose a Country.
UCB announces U.S. FDA approvals for BIMZELX[®] (bimekizumab …
2024年9月23日 · With three new indications, BIMZELX ® (bimekizumab-bkzx) is the first and only IL-17A and IL-17F inhibitor approved in the U.S. for the treatment of four chronic immune-mediated inflammatory diseases.
UCB announces U.S. FDA approval of ZILBRYSQ[®] (zilucoplan) for …
2023年10月17日 · With the FDA approval of zilucoplan, and with RYSTIGGO ® (rozanolixizumab-noli) already FDA approved and launched in the U.S 3, UCB is the first organization to offer the U.S. gMG community the opportunity to benefit from a choice of two new targeted therapies from a single company.
UCB announces U.S. FDA approval of RYSTIGGO[®] …
2023年6月27日 · FDA approval of RYSTIGGO ® (rozanolixizumab-noli) has been granted under the Priority Review designation for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive 1. U.S. FDA approval is based on the pivotal Phase 3 ...
UCB - sustaining growth, now and into the future
Outlook for 2025: For the first time UCB shares its growth ambition for 2025, despite upcoming patent expirations. Based on the strong product portfolio and the promising late-stage pipeline assets, UCB aims to lead in specific populations by 2025, creating value for …
UCB and Biogen Announce Positive Topline Results From Phase 3 …
2024年9月24日 · UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024. Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe systemic lupus erythematosus; Clinical …
UCB expands innovation footprint with new state-of-the-art gene …
Brussels (Belgium), 8th March 2022, 07:00 (CET) – UCB, a global biopharmaceutical company, today announced it will build an innovative and environmentally sustainable gene therapy process development and clinical manufacturing facility on their high-tech campus in Braine l’Alleud, Wallonia, Belgium. The new facility, representing an ...
UCB Completes Acquisition of Zogenix, Inc.
Brussels (Belgium), 7 March 2022– 18:00 (CET) - UCB (Euronext: UCB) today announced the successful completion of the previously announced transaction to acquire Zogenix (NASDAQ: ZGNX) for US$ 26.00 per share plus a milestone-based contingent value right for a potential cash payment of US$ 2.00 per share. The total transaction is valued at up ...